Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.61 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.61 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.61 |
| ▸ | AR | P10275 | 1/20 | 0.57 |
| ▸ | PELP1 | Q8IZL8 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | THRA | P10827 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | USP10 | Q14694 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6870341 | 0.95 | AKR1C3 (0.56) | AKR1C3AKR1C2AKR1C1ARPELP1 | |
| SCHEMBL11949145 | 0.93 | AR (0.58) | AKR1C3AKR1C2AKR1C1ARPELP1 | |
| SCHEMBL8169431 | 0.90 | AR (0.60) | AKR1C3AKR1C2AKR1C1ARPELP1 | |
| SCHEMBL17512386 | 0.90 | THRA (0.60) | AKR1C3AKR1C2AKR1C1LMNAVCAM1 | |
| SCHEMBL4747285 | 0.89 | AR (0.54) | AKR1C3AKR1C2AKR1C1ARPELP1 | |
| SCHEMBL28158589 | 0.88 | AKR1C3 (0.57) | AKR1C3AKR1C2AKR1C1LMNAPOLB | |
| SCHEMBL8887657 | 0.88 | AR (0.58) | AKR1C3AKR1C2AKR1C1ARPELP1 | |
| SCHEMBL1346767 | 0.88 | AR (0.61) | AKR1C3AKR1C2AKR1C1ARPELP1 | |
| SCHEMBL221362 | 0.88 | AR (0.61) | AKR1C3AKR1C2AKR1C1ARPELP1 | |
| SCHEMBL7354751 | 0.87 | AR (0.55) | AKR1C3AKR1C2AKR1C1ARPELP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113185419-B | Synthetic method of oxybuprocaine hydrochloride | 扬州中宝药业股份有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-113185419-A | Synthetic method of oxybuprocaine hydrochloride | 扬州中宝药业股份有限公司 | 2021-07-30 | — | — | CN | disclosed |
| EP-2507243-B1 | SPIROINDOLINONE PYRROLIDINES | HOFFMANN LA ROCHE (CH) | 2015-06-10 | — | — | EP | disclosed |
| CN-102741257-A | Spiroindolinone pyrrolidines | HOFFMANN LA ROCHE | 2012-10-17 | — | — | CN | disclosed |
| EP-2507243-A1 | SPIROINDOLINONE PYRROLIDINES | F. Hoffmann-La Roche AG (CH) | 2012-10-10 | — | — | EP | disclosed |
| US-8088815-B2 | Spiroindolinone pyrrolidines | HOFFMAN-LA ROCHE INC. (US) | 2012-01-03 | — | — | US | disclosed |
| WO-2011067185-A1 | SPIROINDOLINONE PYRROLIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| US-20110130398-A1 | SPIROINDOLINONE PYRROLIDINES | BARTKOVITZ DAVID JOSEPH | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130398-A1 | SPIROINDOLINONE PYRROLIDINES | RPS4Y1, RB1, RPS4X | AKR1C3 447/4885AKR1C2 400/4885AKR1C1 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.